The safety core battery of pharmacology studies to support Phase I clinical trials includes the assessment of effects on cardiovascular, central nervous and respiratory systems.

They permit to evaluate the vital functions as required, and should generally be conducted before human exposure, in accordance with international guidelines ICH S7A and S7B.